Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension

0095729 - FGÚ 2008 RIV CZ eng J - Journal Article
Šimko, F. - Matúšková, J. - Ľupták, I. - Pinčíková, T. - Krajčírovičová, K. - Štvrtina, S. - Pomšár, J. - Pelouch, V. - Paulis, L. - Pecháňová, Olga
Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension.
[Spironolakton ovlivňuje odlišně remodelaci levé komory a aorty u L-NAME-indukované hypertenze.]
Physiological Research. Roč. 56, Suppl.2 (2007), S25-S32. ISSN 0862-8408. E-ISSN 1802-9973
Grant - others:VEGA(SK) 1/3429/06; VEGA(SK) 2/6148/26; -(SK) APVT-51-027404
Institutional research plan: CEZ:AV0Z50110509
Keywords : spironolacton * NO-deficient hypertension * remodeling of LV and aorta
Subject RIV: FA - Cardiovascular Diseases incl. Cardiotharic Surgery
Impact factor: 1.505, year: 2007

The aldosterone receptor antagonist spironolactone improved NO production and partially prevented hypertension and LVH development without preventing hypertrophy of aorta in NO-deficient hypertension. The reactive growth of the heart and aorta seems to be controlled by different mechanisms in L-NAME-induced hypertension

Antagonista aldosteronového receptoru spironolakton zlepšuje produkci oxidu dusnatého a částečně brání rozvoji hypertenze a hypertrofie levé srdeční komory (nikoliv však aorty) u NO-deficitní hypertenze. Růst srdce a aorty se u L-NAME hypertenze zdá být kontrolován odlišnými mechanismy
Permanent Link: http://hdl.handle.net/11104/0155248